Poster Session 1 — ASN Events

Poster Session 1 — ASN Events

Poster Session 1

Note: Posters are still to be allocated to their specific sessions. Check back closer to the Meeting for the final allocations.

Streptococcus dysgalactiae subsp. equisimilis carriage and infection epidemiology and risk factors in The Gambia (#101)

Optimising the detection of Streptococcus pyogenes events in surveillance studies: intensive swabbing and PCR within the SpyCATS study (#102)

Tracking the relationship between community Strep A infections and Acute Rheumatic Fever in Auckland, New Zealand: 2018-2024 (#103)

Differential Immune Response in Children to Throat Specialist Versus Generalist Group A Streptococci (#104)

Antimicrobial susceptibility of Streptococcus pneumoniae isolated from sputum of patients presenting at patan hospital (#105)

Saugat Bhandari

Molecular epidemiology of superficial Streptococcus pyogenes infections in the SToP trial Western Australia (#106)

Clinical and Microbiological Characteristics of Facial Infections Caused by Streptococcus spp. (#107)

Expansion scarlet fever-associated mobile genetic elements among group A Streptococcus in Taiwan (#108)

Chuan Chiang-Ni

Inference of Streptococcus pyogenes transmission pathway parameters from analyses of whole genome sequence data of isolates collected in a high burden setting (#109)

Rebecca H Chisholm

Large chromosomal rearrangements affect protein expression and are associated with invasive disease in Streptococcus pyogenes (#110)

Matthew A Davies

Household molecular epidemiology of Streptococcus pyogenes carriage and infection in The Gambia (#111)

Gabrielle de Crombrugghe

Household molecular epidemiology of Streptococcus dysgalactiae subsp. equisimilis carriage and infection in The Gambia (#112)

Gabrielle de Crombrugghe

M1 and done? Converging on a globally representative set of more and less invasive group a streptococcal strains (#113)

Gabrielle de Crombrugghe

School and clinical-based experimentation to ascertain Streptococcus pyogenes (Strep A) transmission (#114)

Stephanie Enkel

Cross-sectional analysis of streptococcal serology in a global cohort of ARF and Healthy Children (#115)

Analysis of the scabies associated microbiota demonstrates a decrease in diversity and a shift to opportunistic pathogenic bacteria (#116)

Setting the scene for Group A Streptococcus vaccine studies: The complete clinical spectrum of severe acute disease is present in Auckland, Aotearoa New Zealand (#117)

Andrew Fox-Lewis

Invasive Group A Streptococcus (iGAS) surveillance gets the green light: a clear-cut microbiological specimen sterility framework for comprehensive and consistent laboratory surveillance. (#118)

Andrew Fox-Lewis

NEARER SCAN evaluation of a task-sharing echocardiographic active case finding program for rheumatic heart disease in Australia and Timor-Leste: interim findings from a hybrid type II effectiveness-implementation study (#119)

Joshua R Francis

Invasive group A streptococcal infections in Australian adults – a descriptive cohort and cost burden study (#120)

Jessie J Goldsmith

Asymptomatic throat and vaginal carriage and household transmission of beta-haemolytic streptococci during pregnancy: a prospective cohort study (#121)

Kirsi Gröndahl-Yli-Hannuksela

Trends in Invasive Pneumococcal Disease in Nepalese Children: Evaluating the Impact of 10-Valent Pneumococcal Conjugate Vaccine Introduction (2014–2023) (#122)

Descriptive analysis of incidence, hospital acquisition and health inequalities in invasive group C and G streptococcal infections England, 2016 to 2023 (#123)

Streptococcal brain abscesses: assessing a decade of trends in England between 2014 and 2023 (#124)

Outcomes after concomitant mitral and aortic rheumatic valve surgery in the young. (#125)

Hilary Hardefeldt

The Australian Strep A Vaccine Initiative (ASAVI) Urban Pharyngitis Surveillance Study (#126)

Epidemiology and clinical research on group a streptococcus: a public health perspective (#127)

Aliyu Evuti Haruna

The rise of invasive group A streptococcal infection in a quaternary Australian hospital (#128)

Antimicrobial effect of photo activated disinfection on streptococcus from endodontic infections (#129)

Genomic insights into horizontal transfer of macrolide resistance among Streptococcus pneumoniae via mobile integrative conjugative elements following azithromycin mass drug administration in Malawi (#130)

Akuzike Kalizang'oma

Investigating differential maternal GBS carriage according to ethnicity: cross-sectional analysis nested within a multicentre randomised clinical trial in England (#131)

Theresa Lamagni

Effecting control of a widespread emm11 GAS outbreak linked to community healthcare services in the East of England, 2023-25 (#132)

Theresa Lamagni

Epidemiology of Group A Streptococcal Skin Infections in New Zealand (#133)

Krishtika KM Mala

A molecular epidemiology of invasive Group A Streptococcus (iGAS) infection detected within the Hunter New England Local Health District (HNELHD) of New South Wales (NSW), Australia from 2007 to 2017 (#134)

Population pharmacokinetics of penicillin G: insights into increased clearance at low concentrations to guide development of improved long-acting formulations for syphilis and prevention of rheumatic fever (#135)

Laurens Manning

Predictors of Clinical Outcomes in Acute Rheumatic Fever in the Contemporary Era: The Role of Erythrocyte Sedimentation Rate (#136)

A collaborative inter-departmental study confirming the usefulness of high-resolution WGS data in informing Group A Streptococcus pyogenes (GAS) outbreaks (#137)

Kartyk Moganeradj

A Proposed Chatbot as a Tool for Acute Rheumatic Fever Screening Across Four Countries *On behalf of the Acute Rheumatic Fever Diagnostic Network (ARC Network) (#138)

Isabella Moreira Gonzalez Fonesca, MD

Challenges in acute rheumatic fever management A case of severe carditis and recurrence (#139)

Isabella Moreira

Cracking the nut of clinical trials to test interventions for life threatening gram-positive toxin-mediated syndromes (#140)

Hadar Mudrik-Zohar

Genomic epidemiology, antimicrobial resistance and virulome of invasive Group B Streptococcus isolates in Hunter Region, NSW, Australia. (#141)

Invasive group A streptococcus and respiratory viral coinfections in Alberta, Canada from 2018 to 2024. (#142)

High rates of group A streptococcal pharyngitis among a longitudinal cohort of school-aged children in remote Western Australia (#143)

Janessa Pickering

Evaluation of CRISPR elements in group B Streptococcus belonging to ST17 from Brazil (#144)

Report of a host-generalist group B Streptococcus lineage (CC103) associated with severe disease in primate and human in Brazil: the potential threat to public health (#145)

Diverse diagnostic and management approaches for acute rheumatic fever in Australia and New Zealand (#146)

High propensity for multidrug-resistant pneumococcal aerosol shedding among adults living with HIV in Malawi: A Microbial Diversity Analysis (#147)

Lusako L Sibale

Streptococcus agalactiae bacteremia and the utility of time to positivity - an observational study in southern Sweden (#148)

Torgny Sunnerhagen

Prevalence, risk factors, and strain distribution of group A Streptococcus carriage among Indigenous children in the Southwest United States (#149)

Catherine Sutcliffe

Genomic Characterization and Classification of Streptococcus oralis Using Next-Generation Sequencing (#150)

Genomic characteristics and antimicrobial resistance of Streptococcus agalactiae isolates causing infections and asymptomatic carriage in Southwest Finland (#151)

Natalie Tomnikov

A systematic review of asymptomatic colonisation with Group A Streptococcus in low and middle income countries (#152)

Hermaleigh Townsley

Update on invasive group A streptococcus hypervirulent M1_UK clone in Canada 2024 (#153)

Gregory Tyrrell

The Emergence and Impact of M1_UK on Invasive Group A Streptococcus Disease in Aotearoa New Zealand (#154)

Genomic epidemiology of S. pyogenes carriage and pharyngitis isolates from the STAMPS Australian paediatric surveillance study (#155)

Effect of prior antibiotics use on blood culture positivity in children under 5 years with suspected invasive pneumococcal diseases in rural Gambia (#156)

Severe GAS infections in pregnancy and the peripartum period in South Auckland, New Zealand, 2023. (#157)

Severe paediatric invasive group A streptococcal infections at Starship Children’s Hospital, Auckland, Jan 2023 - Jan 2025 (#158)

Historical Evidence for Streptococcus pyogenes as the Causative Agent of Acute Rheumatic Fever: A Structured Narrative Review (#159)

Distribution of pneumococcal serotypes causing invasive disease and carriage in rural Gambia in the post-vaccination era (#160)

Baleng Mahama Wutor

Understanding current clinical guidance about delivery of benzathine penicillin G (#161)

Strategic and scientific contributions of human challenge trials for Strep A vaccine development: facts versus fantasy (#162)

Yara-Natalie Abo

Development of a High-Performance Anion Exchange Chromatography Method for PolyRhamnose Quantification in Group A Streptococcus Vaccines. (#163)

CHIVAS-M1: No strain, no gain. Choosing an M1_UK human challenge strain. (#164)

Kristy I Azzopardi

Vaccinee-derived monoclonal antibodies against GBS highlight functional clusters on the AlpN antigens (#165)

"iSOoTH: A study on children's sore throats to inform the development of a Group A Streptococcal vaccine (#166)

Towards a Human Whole Blood in Tube Assay to Measure Cellular Immunity to Streptococcus pyogenes Vaccine Antigens (#167)

Natalie Caltabiano

Putting public enemy #M1_UK in the human challenge crosshairs (#168)

Developing a new Vaccine against Streptococcus Pyogenes (#169)

Jes JDI Dietrich

The ‘RHAPSEDA’ Platform for the Recombinant Production of Affordable and Universal Glycoconjugate Vaccines for Strep A (#170)

Helge C Dorfmueller

Discovery-based approaches to advance mucosal vaccine strategies against Strep A (#171)

Maria Emilia Duenas

Hospitalisation rate of clinical pneumococcal disease among under-five-children in Haryana, India: A seven-year multicentric bidirectional surveillance study (#172)

Investigating correlates of protection in the non-human primate model of pharyngitis by comparison of Combo#5 vaccines adjuvanted with Alum and SMQ (#173)

Steven J Hancock

Systems approach to group A streptococcal vaccine discovery using saRNA (#174)

Advancing group a streptococcus vaccine development: immunological insights and prospects for implementation in nigeria (#175)

Aliyu Evuti Haruna

Development of a whole blood assay to detect Group A Streptococcus (GAS) specific T cell responses and application to school-based studies in The Gambia (#176)

Ya Jankey Jagne

Safety and immunogenicity of a Group B Streptococcus vaccine in participants aged 55-75 years (#177)

Bengt Johansson Lindbom

Investigating the role of antibodies to emm type-specific M peptides in natural immunity to Streptococcus pyogenes in The Gambia (#178)

Alexander Keeley

Functional immunoassay performance across the life course in the Gambia: association with binding IgG titre to vaccine antigens (#179)

Alexander Keeley

Antibody responses to Streptococcus pyogenes in UK adults over the COVID-19 pandemic period (#180)

An update on pilus-based vaccine development to prevent Group A Streptococcal infections (#181)

Where did all the antibodies go? Exploring Immunity Gaps to Group A Streptococcus and other endemic respiratory pathogens following pandemic Restrictions in Aotearoa New Zealand (#182)

A streptococcal vaccine to prevent cellulitis in older adults (#183)

Laurens Manning

A Clinically Relevant Cationic Adjuvant System Induces Th17 T Cells Involved in Skin and Upper Airway Infections with Streptococcus pyogenes (#184)

Kristoffer Mazanti Melchiors

System Serology Reveals Correlates of Functional Group A Streptococcus Antibody Responses In Children With Pharyngitis (#185)

Reuben McGregor

Antibody Responses to Streptococcus pyogenes antigens in an Australian Longitudinal Paediatric Cohort Study (#186)

Parenteral vaccination with a super immunogen targeting M-protein provides unprecedented protection against group A streptococcus (StrepA) respiratory infections (#187)

Victoria Ozberk

Developing a Next-Generation Vaccination Strategy Leveraging Traditional Approaches to Combat Streptococcus pyogenes (StrepA) Infections (#188)

Building laboratory capacity to advance Strep A vaccine development in Aotearoa New Zealand (#189)

Survival to opsonophagocytosis killing assay (OPKA) of group B Streptococcus strains recovered in Brazil (#190)

Colonization with Streptococcus pyogenes elicits robust B cell responses against conserved vaccine antigens in paediatric tonsils (#191)

Optimizing formulation of the Group A Streptococcus mRNA vaccine candidate Combo#5 (#192)

Brody Pullinger

Characterizing protective immune responses following repetitive nasopharyngeal infections by Streptococcus pyogenes in HLA-transgenic mice (#193)

Human serological assays characterization to evaluate the response against Group A Streptococcus vaccine in clinical trial sera (#194)

Analysis of technologies to produce glycoconjugate vaccines against Group A Streptococcus (#195)

Genomic surveillance of Streptococcus pneumoniae and Streptococcus pyogenes in the Czech Republic in the Post-COVID era (#196)

Sandra Vohrnová